Pfizer v. Apotex: IBRANCE Palbociclib Patent Action Dismissed in 42 Days
Pfizer and co-plaintiffs Warner-Lambert and PF PRISM IMB filed suit against Apotex in Delaware over reissue patent USRE047739E covering IBRANCE (palbociclib) tablets at 75 mg, 100 mg, and 125 mg dosages. The action was voluntarily dismissed without prejudice just 42 days after filing — before Apotex served any answer — leaving Pfizer’s litigation options open.
A strategic early exit in Pfizer’s palbociclib ANDA defence
On 20 June 2025, Pfizer Inc., Warner-Lambert Company LLC, and PF PRISM IMB B.V. filed an infringement action in the Delaware District Court against Apotex Inc. and Apotex Corp. (Case No. 1:25-cv-00765) before Judge Colm F. Connolly. The asserted patent — USRE047739E, a reissue patent corresponding to US application 16/048143 — covers the blockbuster CDK4/6 inhibitor palbociclib, marketed as IBRANCE in 75 mg, 100 mg, and 125 mg tablet formulations.
On 1 August 2025, just 42 days after filing, Pfizer and co-plaintiffs filed a notice of voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), dismissing all claims without prejudice. The filing confirmed that Apotex had not yet served an answer or motion for summary judgment, meaning the dismissal was available as a unilateral right — no court approval was required. The without-prejudice designation is legally significant: Pfizer is not barred from reasserting the same patent claims against Apotex in a future action.
The 42-day resolution is notably brief even for early-stage ANDA disputes, which typically trigger automatic 30-month stays following timely filing. The public record does not disclose a settlement agreement, licensing arrangement, or ANDA withdrawal, leaving the precise commercial driver opaque. Possible explanations include a licensing resolution, a change in Apotex’s ANDA strategy, or a tactical decision by Pfizer to restructure its enforcement approach — none of which can be confirmed from the docket alone.
Filing to Dismissed without Prejudice in 42 days
42 days — case resolved well before typical ANDA litigation timelines of 2–4 years
Voluntarily dismissed without prejudice: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i) — a unilateral right to exit before answer
Federal Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without court order if the defendant has not yet served an answer or motion for summary judgment. Pfizer’s notice confirms Apotex had not done so. This means the dismissal required no judicial approval and carries no merits adjudication — the court made no ruling on infringement, validity, or enforceability of USRE047739E.
No merits rulingWithout prejudice: the distinction matters commercially
A dismissal without prejudice does not extinguish Pfizer’s claims — the same patent can be reasserted against Apotex in a future action. A dismissal with prejudice would have permanently barred refiling. The public record is silent on whether any side agreement constrains Pfizer’s ability to refile; that context, if it exists, is not reflected in the docket. Parties and counsel should not assume a commercial resolution occurred without further evidence.
Refile right preservedApotex exits without a merits win — but faces ongoing risk
Because the dismissal is without prejudice, Apotex cannot claim a court-validated freedom to launch its generic palbociclib product. No finding of non-infringement or invalidity was made. If Apotex proceeds toward ANDA approval and commercial launch, Pfizer retains the option to refile and seek a new 30-month stay or preliminary injunction. Apotex’s exposure under USRE047739E remains live.
Launch risk unresolvedIBRANCE generic entry still uncertain after early dismissal
IBRANCE (palbociclib) is a high-value oncology asset; generic entry would significantly erode Pfizer’s market position. The rapid, without-prejudice exit suggests the parties may be negotiating — or that Pfizer is repositioning its litigation strategy. Other ANDA filers in the palbociclib space should monitor whether Pfizer refiles or pursues additional patents. The reissue patent designation of USRE047739E also signals Pfizer has already broadened or corrected its claims once.
Generic entry risk ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global pharmaceutical company — holder of USRE047739E covering IBRANCE (palbociclib)Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Canadian generic pharmaceutical manufacturer and US subsidiary filing ANDA for palbociclib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly confirms Apotex had not answered, making the dismissal a unilateral procedural act rather than a negotiated court order. The without-prejudice designation is the operative legal term: no claim is extinguished, no infringement finding was made, and USRE047739E remains fully assertable. The explicit identification of all three plaintiffs and both Apotex entities suggests counsel took care to ensure the dismissal’s scope is precise and complete as to this action.
USRE047739E — palbociclib CDK4/6 inhibitor, IBRANCE tablet formulations
USRE047739E is a United States reissue patent corresponding to application US16/048143. As a reissue, it reflects a post-grant correction or claim refinement by the USPTO, typically pursued when a patentee believes the original patent was partially defective — through over-claiming or under-claiming. The underlying technology covers palbociclib, a CDK4/6 inhibitor used in the treatment of hormone receptor-positive, HER2-negative breast cancer. IBRANCE is marketed in three dosage strengths: 75 mg, 100 mg, and 125 mg tablets.
Palbociclib was the first CDK4/6 inhibitor approved by the FDA and remains one of Pfizer’s most commercially significant oncology assets. The reissue patent designation elevates enforcement risk: the claim set has been reviewed and refined, giving Pfizer a more durable infringement position. Generic manufacturers targeting this market must analyse the reissued claims carefully — particularly any broadened claim language introduced during reissue proceedings — before filing ANDAs or initiating Paragraph IV certifications.
Should you run an FTO against USRE047739E before entering the palbociclib market?
Any company developing a generic, biosimilar-adjacent, or next-generation CDK4/6 inhibitor product — particularly in oral tablet form — should treat USRE047739E as a primary FTO target. The reissue history means the claim scope may differ materially from the original patent. Given that this case was dismissed without prejudice, Pfizer’s enforcement posture is unresolved, and the risk of rapid refiling is real. Product teams advancing palbociclib-related compounds toward IND or ANDA filing should not rely on the absence of an active case as clearance.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map the current claim scope of USRE047739E, identify prosecution history estoppel from the reissue proceedings, and benchmark against the broader CDK4/6 inhibitor patent landscape. Automated monitoring alerts can flag any refile by Pfizer or related continuation activity — giving your team the advance notice needed to adjust development or launch strategy before a new 30-month stay is triggered.
Run a freedom-to-operate analysis on USRE047739E to assess your product’s exposure
Run FTO in Eureka →Similar CDK4/6 inhibitor ANDA patent cases in Delaware District Court
Explore related pharmaceutical patent infringement actions involving CDK4/6 inhibitors and ANDA defendants litigated in the Delaware District Court.
What this case signals for the oncology generics IP landscape
A 42-day without-prejudice exit in a high-stakes ANDA case rarely signals surrender — it typically signals repositioning.
Without-prejudice dismissals in ANDA cases preserve full enforcement leverage
Pfizer’s use of Rule 41(a)(1)(A)(i) before Apotex answered means no merits record was created. This preserves Pfizer’s ability to refile, select a more favourable timing, or assert additional patents. Generic entrants should not treat an early voluntary dismissal as a green light for commercial launch without a formal licence or covenant not to sue.
Reissue patents signal refined claim scope — a heightened enforcement risk
USRE047739E is a reissue patent, meaning the USPTO already reviewed and corrected or broadened the original claims. This typically signals the patent holder has optimised the claim set for enforcement. Companies developing CDK4/6 inhibitor generics or next-generation compounds should conduct FTO analysis against the reissued claim scope specifically, not merely the original patent.
Pfizer v Apotex — key questions answered
The without-prejudice dismissal means Pfizer did not permanently relinquish its infringement claims under USRE047739E. Apotex received no court-validated freedom to launch. Pfizer can refile the same claims, potentially triggering a new 30-month ANDA stay. No merits ruling on infringement or validity was issued.
USRE047739E is a reissue patent covering palbociclib (IBRANCE) formulations, corresponding to US application 16/048143. Reissue status means the USPTO reviewed and refined the original claims. This typically indicates the patentee has optimised claim scope for enforcement, making invalidity and non-infringement arguments more difficult for generic challengers to sustain.
The public record does not disclose the commercial reason for the early dismissal. Pfizer filed the notice under Rule 41(a)(1)(A)(i) before Apotex answered, exercising a unilateral right. Possible explanations include a licensing agreement, ANDA withdrawal by Apotex, or a tactical litigation repositioning — none confirmed by the docket.
Yes. A dismissal without prejudice under Rule 41(a)(1)(A)(i) does not bar refiling. Pfizer retains the right to reassert USRE047739E against Apotex in a new action. If Apotex’s ANDA contains a Paragraph IV certification, a timely refile could trigger a new 30-month stay of FDA approval.
The plaintiffs are Pfizer Inc., Warner-Lambert Company LLC, and PF PRISM IMB B.V. The defendants are Apotex Inc. and Apotex Corp. The case was filed in the Delaware District Court before Judge Colm F. Connolly and dismissed on 1 August 2025.
PatSnap Eureka searches patents and litigation data to answer instantly.